Precision Epidemiology for AstraZeneca Cardiovascular Launches
Define and size “at-risk” populations using clinical-grade thresholds—not diagnosis codes. Quantify the economic burden and unmet need for baxdrostat and laroprovastat using longitudinal BP, LDL, and lab-integrated real-world evidence.
The Challenge
Solving the “ICD Code Gap” in Evidence Research
The Phenotype Identification Gap
Beyond ICD-10 Coding: Traditional claims often miss the clinical nuances your assets require. We bridge this gap by integrating actual laboratory and vitals-based thresholds, ensuring your Phase III cardiovascular trials target the precise clinical phenotypes they were designed for.
High-Fidelity Budget Impact Modeling
Data-Driven Market Sizing: Move beyond estimates to high-confidence Budget Impact Analysis (BIA). By merging medical claims with specialty EHR and lab data, we empower HEOR teams to substantiate the true economic and clinical scale of their addressable markets.
Navigating the Market Access Hurdle
Payer-Ready Evidence: Secure favorable HTA and ICER reviews with a research-grade foundation. Our platform provides the transparent, auditable data required to prove long-term value, helping you navigate complex international reimbursement negotiations with ease.
Solving with Komodo
Multi-Functional Evidence Solutions
Longitudinal Outcomes Research
Mapping the Patient Journey: Visualize the long-term impact of cardiovascular disease with 7-year clinical narratives. We track the direct progression from uncontrolled hypertension and LDL levels to Major Adverse Cardiovascular Events (MACE).
Clinical Phenotyping & Targeting
Beyond Diagnosis Codes: Precisely pinpoint high-risk cohorts for therapies like Baxdrostat. We track actual blood pressure measurements in patients on stable regimens to distinguish true resistant hypertension from general diagnosis codes.
Market Assessment & Gap Analysis
Identifying Clinical Gaps: Quantify the addressable ASCVD population by identifying patients who remain above LDL-C goals despite maximum-statin therapy—transforming clinical data into a clear market opportunity for Laroprovastat.
Precision Economic Outcomes
Regulatory-Grade Evidence: Build high-confidence HCRU and cost-effectiveness models with a 95%+ cost fill rate. Every analysis is backed by visible SQL/R code, ensuring your payer dossiers are fully transparent, auditable, and publication-ready.
The Komodo Impact
Evidence That Drives Global Value Demonstration
Accelerated Evidence Velocity
Shave 4–9 months off research timelines for drugs like baxdrostat and laroprovastat by utilizing pre-integrated lab and EHR specialty data.
Validated Budget Impact Models
Generate “payer-ready” BIA estimates using clinical thresholds, capturing the entire addressable population often missed by ICD-only analysis.
Representative, Context-Driven Epidemiology
Ensure cardiovascular value stories are both generalizable and scientifically grounded by utilizing a dataset aligned 95–98% with U.S. Census demographics, further contextualized by native integration with PubMed and ClinicalTrials.gov.
Resources
Read more about how Komodo’s robust product suite can help you unlock your team’s expertise and accelerate decision-making across the enterprise.
AI Reliability Guide
Guide
Komodo Health’s HEOR Methodology
WHITE PAPER
How Marmot Delivers Enterprise Wide ROI
Perspectives
Gain Your Velocity Advantage for Cadriovascular Evidence
Standardize your evidentiary backbone and move from top-down estimates to clinical-grade epidemiology for Phase III. Experience a higher standard of rigor in cardiovascular outcomes research.